About PREDILIFE

Company Description

Pioneers of predictive medicine in France, we position ourselves as a player in 6P medicine: Predictive, Preventive, Personalized, Participative, Relevant, Multi-professional.

After 14 years of research and development, Predilife obtained its medical device certification and began marketing predictive assessments: predictive breast cancer assessment, multi-pathology predictive assessments.

At Predilife, we are passionate about serving health, a committed team that works every day to change the rules so that our motto "predict to prevent" is adopted by the greatest number of people.

We accompany companies, healthcare professionals and employees towards the medicine of tomorrow: predictive, personalized and digital. We are working to make predictive medicine accessible to everyone in order to reduce the number of serious diseases.

We believe that predictive medicine will enable effective prevention and thus reduce the risk of serious diseases.

Year founded

2004

Served area

Worldwide

Headcount

19

Headquarters

39 Rue Camille Desmoulins, 94800 Villejuif – France

Shareholder information

Shares outstanding

3,660,305

IPO

Dec. 21, 2018

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.